Items tagged with Access
Activists demand Johnson & Johnson drop the price of bedaquiline (post with simple image)
Activists storm the corporate stall of Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) at the 9th South African AIDS Conference.
MSF technical brief: A rapid TB test for people living with HIV (post with simple image)
TB LAM can help close the deadly TB testing gap.
Beware the Global Fund procurement cliff (post with simple image)
Safeguarding supply of affordable quality medicines and diagnostics in context of risky transitions and co-financing.
Activists demand universal access to medicines — science must benefit all! (post with simple image)
Life without medicines is no party: Activists call on governments across the world to join the #Science4All “party” to make treatment available to all.
Transparency and access to pretomanid and the Nix-TB regimen (post with simple image)
Advocates request responsible investment in pretomanid promoting transparency and equitable access.
FDA approves pretomanid for highly drug-resistant forms of TB (post with simple image)
Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
TB drug delamanid must be more affordable and made available in more countries (post with simple image)
Médecins Sans Frontières acknowledges the lower price offered to the government of South Africa for delamanid, but calls for it to be significantly lower and expanded to all countries in need.
Global campaign launched urging Johnson & Johnson to reduce price of bedaquiline (post with simple image)
Médecins Sans Frontières launches a global campaign calling on Johnson & Johnson to lower the price of bedaquiline to no more than US$1 per day.
Time to lower the price of Xpert cartridges to $5 (post with simple image)
Advocates request Cepheid immediately reduce the price of Xpert tests to $5, inclusive of service and maintenance; Cepheid claims costs for each Xpert cartridge "substantially exceed" the requested price target of $5, but does not provide evidence to support this claim.
DR-TB Drugs Under the Microscope, 6th edition (post with simple image)
Médecins Sans Frontières releases the 6th edition of DR-TB Drugs Under the Microscope: 5 Urgent Actions to Improve DR-TB Treatment.
Page 63 of 65 · Total posts: 0←First 62 63 64 Last→